BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

177 related articles for article (PubMed ID: 34880297)

  • 1. Characterization of the humoral immune response to the EBV proteome in extranodal NK/T-cell lymphoma.
    Liu Z; Sarathkumara YD; Chan JKC; Kwong YL; Lam TH; Ip DKM; Chiu BC; Xu J; Su YC; Proietti C; Cooper MM; Yu KJ; Bassig B; Liang R; Hu W; Ji BT; Coghill AE; Pfeiffer RM; Hildesheim A; Rothman N; Doolan DL; Lan Q
    Sci Rep; 2021 Dec; 11(1):23664. PubMed ID: 34880297
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Genome-Wide Analysis of Epstein-Barr Virus Isolated from Extranodal NK/T-Cell Lymphoma, Nasal Type.
    Lin N; Ku W; Song Y; Zhu J; Lu Z
    Oncologist; 2019 Sep; 24(9):e905-e913. PubMed ID: 30940744
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparative Analysis of the Humoral Immune Response to the EBV Proteome across EBV-Related Malignancies.
    Argirion I; Pfeiffer RM; Proietti C; Coghill AE; Yu KJ; Middeldorp JM; Sarathkumara YD; Hsu WL; Chien YC; Lou PJ; Wang CP; Rothman N; Lan Q; Chen CJ; Mbulaiteye SM; Jarrett RF; Glimelius I; Smedby KE; Hjalgrim H; Hildesheim A; Doolan DL; Liu Z
    Cancer Epidemiol Biomarkers Prev; 2023 May; 32(5):687-696. PubMed ID: 36788424
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Analysis of latent T-cell epitopes in Epstein-Barr virus isolated from extranodal nasal-type natural killer/T-cell lymphoma in Taiwanese population.
    Chou CC; Tsao CF; Liao CK; You HL; Wang MC; Huang WT
    Exp Mol Pathol; 2021 Feb; 118():104577. PubMed ID: 33242451
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Serum EBV EA-IgA and VCA-IgA antibodies can be used for risk group stratification and prognostic prediction in extranodal NK/T cell lymphoma: 24-year experience at a single institution.
    Huang Y; Rao H; Yan S; Wang F; Wu Q; Feng Y; Zhang Y
    Ann Hematol; 2017 Aug; 96(8):1331-1342. PubMed ID: 28550598
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Evaluation of the antibody response to the EBV proteome in EBV-associated classical Hodgkin lymphoma.
    Liu Z; Jarrett RF; Hjalgrim H; Proietti C; Chang ET; Smedby KE; Yu KJ; Lake A; Troy S; McAulay KA; Pfeiffer RM; Adami HO; Glimelius B; Melbye M; Hildesheim A; Doolan DL; Coghill AE
    Int J Cancer; 2020 Aug; 147(3):608-618. PubMed ID: 31618442
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Genomic and transcriptomic landscapes of Epstein-Barr virus in extranodal natural killer T-cell lymphoma.
    Peng RJ; Han BW; Cai QQ; Zuo XY; Xia T; Chen JR; Feng LN; Lim JQ; Chen SW; Zeng MS; Guo YM; Li B; Xia XJ; Xia Y; Laurensia Y; Chia BKH; Huang HQ; Young KH; Lim ST; Ong CK; Zeng YX; Bei JX
    Leukemia; 2019 Jun; 33(6):1451-1462. PubMed ID: 30546078
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Anti-Epstein-Barr virus antibodies in Beijing during 2013-2017: What we have found in the different patients.
    Cui J; Yan W; Xu S; Wang Q; Zhang W; Liu W; Ni A
    PLoS One; 2018; 13(3):e0193171. PubMed ID: 29494658
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Increased T-cell responses to Epstein-Barr virus with high viral load in patients with Epstein-Barr virus-positive diffuse large B-cell lymphoma.
    Morishima S; Nakamura S; Yamamoto K; Miyauchi H; Kagami Y; Kinoshita T; Onoda H; Yatabe Y; Ito M; Miyamura K; Nagai H; Moritani S; Sugiura I; Tsushita K; Mihara H; Ohbayashi K; Iba S; Emi N; Okamoto M; Iwata S; Kimura H; Kuzushima K; Morishima Y
    Leuk Lymphoma; 2015 Apr; 56(4):1072-8. PubMed ID: 24975317
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The Association between the Comprehensive Epstein-Barr Virus Serologic Profile and Endemic Burkitt Lymphoma.
    Coghill AE; Proietti C; Liu Z; Krause L; Bethony J; Prokunina-Olsson L; Obajemu A; Nkrumah F; Biggar RJ; Bhatia K; Hildesheim A; Doolan DL; Mbulaiteye SM
    Cancer Epidemiol Biomarkers Prev; 2020 Jan; 29(1):57-62. PubMed ID: 31619404
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Identification of a Novel, EBV-Based Antibody Risk Stratification Signature for Early Detection of Nasopharyngeal Carcinoma in Taiwan.
    Coghill AE; Pfeiffer RM; Proietti C; Hsu WL; Chien YC; Lekieffre L; Krause L; Teng A; Pablo J; Yu KJ; Lou PJ; Wang CP; Liu Z; Chen CJ; Middeldorp J; Mulvenna J; Bethony J; Hildesheim A; Doolan DL
    Clin Cancer Res; 2018 Mar; 24(6):1305-1314. PubMed ID: 29301829
    [No Abstract]   [Full Text] [Related]  

  • 12. Identification of anti-Epstein-Barr virus (EBV) antibody signature in EBV-associated gastric carcinoma.
    Song L; Song M; Camargo MC; Van Duine J; Williams S; Chung Y; Kim KM; Lissowska J; Sivins A; Gao W; Karthikeyan K; Park J; Leja M; Cohen JI; LaBaer J; Qiu J; Rabkin CS
    Gastric Cancer; 2021 Jul; 24(4):858-867. PubMed ID: 33661412
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Association between Antibody Responses to Epstein-Barr Virus Glycoproteins, Neutralization of Infectivity, and the Risk of Nasopharyngeal Carcinoma.
    Zhu QY; Kong XW; Sun C; Xie SH; Hildesheim A; Cao SM; Zeng MS
    mSphere; 2020 Dec; 5(6):. PubMed ID: 33268566
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evaluation of the role of Epstein-Barr virus in cases of nodal or extranodal T- and NK-cell lymphoma using eber in situ hybridization.
    Karaarslan S; Hekimgil M; Soydan S; Ertan Y; Doğanavşargil B
    Pol J Pathol; 2015 Jun; 66(2):161-9. PubMed ID: 26247530
    [TBL] [Abstract][Full Text] [Related]  

  • 15. PD-L1 is upregulated by EBV-driven LMP1 through NF-κB pathway and correlates with poor prognosis in natural killer/T-cell lymphoma.
    Bi XW; Wang H; Zhang WW; Wang JH; Liu WJ; Xia ZJ; Huang HQ; Jiang WQ; Zhang YJ; Wang L
    J Hematol Oncol; 2016 Oct; 9(1):109. PubMed ID: 27737703
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Serological profiling of the EBV immune response in Chronic Fatigue Syndrome using a peptide microarray.
    Loebel M; Eckey M; Sotzny F; Hahn E; Bauer S; Grabowski P; Zerweck J; Holenya P; Hanitsch LG; Wittke K; Borchmann P; Rüffer JU; Hiepe F; Ruprecht K; Behrends U; Meindl C; Volk HD; Reimer U; Scheibenbogen C
    PLoS One; 2017; 12(6):e0179124. PubMed ID: 28604802
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Single-assay combination of Epstein-Barr Virus (EBV) EBNA1- and viral capsid antigen-p18-derived synthetic peptides for measuring anti-EBV immunoglobulin G (IgG) and IgA antibody levels in sera from nasopharyngeal carcinoma patients: options for field screening.
    Fachiroh J; Paramita DK; Hariwiyanto B; Harijadi A; Dahlia HL; Indrasari SR; Kusumo H; Zeng YS; Schouten T; Mubarika S; Middeldorp JM
    J Clin Microbiol; 2006 Apr; 44(4):1459-67. PubMed ID: 16597877
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Patterns of Interindividual Variability in the Antibody Repertoire Targeting Proteins Across the Epstein-Barr Virus Proteome.
    Liu Z; Coghill AE; Pfeiffer RM; Proietti C; Hsu WL; Chien YC; Lekieffre L; Krause L; Yu KJ; Lou PJ; Wang CP; Mulvenna J; Middeldorp JM; Bethony J; Chen CJ; Doolan DL; Hildesheim A
    J Infect Dis; 2018 May; 217(12):1923-1931. PubMed ID: 29509907
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The Epstein-Barr Virus Oncogene EBNA1 Suppresses Natural Killer Cell Responses and Apoptosis Early after Infection of Peripheral B Cells.
    Westhoff Smith D; Chakravorty A; Hayes M; Hammerschmidt W; Sugden B
    mBio; 2021 Dec; 12(6):e0224321. PubMed ID: 34781735
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Single-Cell Analysis Reveals Malignant Cells Reshape the Cellular Landscape and Foster an Immunosuppressive Microenvironment of Extranodal NK/T-Cell Lymphoma.
    Li YQ; Luo CL; Jiang JX; He S; Liu Y; Yan WX; Xia Y; Cui Q; Huang Y; Lim JQ; Huang D; Hussein IN; Gao Y; Lin GW; Ling YH; Ma D; Zhang YT; Chan JY; Wei PP; Wang XX; Cheng CL; Xiong J; Zhao WL; Ong CK; Lim ST; Huang HQ; Peng RJ; Bei JX
    Adv Sci (Weinh); 2023 Dec; 10(36):e2303913. PubMed ID: 37949673
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.